Related Experiment Video
Updated: Sep 10, 2026

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
Published on: November 23, 2014
Regulation of the pro-angiogenic microenvironment by carboxyamido-triazole
Vyta Kulpa Oliver1, Angela M Patton, Sudhen Desai
1Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892-1500, USA.
Abstract:
Anti-angiogenic agents regulate tumor growth by inhibiting endothelial cell proliferation and invasion. Carboxyamido-triazole (CAI), an inhibitor of non-voltage-operated calcium entry and calcium influx-mediated pathways, has angiogenesis and invasion inhibitory activity. We hypothesized that CAI may express its anti-angiogenic effects through negative regulation of pro-angiogenic cytokine production and/or function. In vivo, orally administered CAI prevented A2058 human melanoma xenograft growth and concomitantly resulted in a marked reduction in circulating vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8). In vitro, A2058 cell secretion of VEGF was inhibited by CAI treatment under limiting micronutrient conditions that approximate the tumor microenvironment, media restriction, and acidification to pH 6.8 (P=0.0003 and P=0.0006, respectively). VEGF and HIF-1alpha message and protein were also reduced by CAI treatment. Oral CAI treatment reduced vascular ingrowth in vivo into VEGF-containing Matrigel plugs. Commensurate with those findings, human umbilical vein endothelial cell (HUVEC) migration towards VEGF was reduced below background by exposure to CAI in the migration chamber (P<0.0001). An 88% reduction in circulating IL-8 concentration was measured in CAI-treated animals. However, IL-8 protein secretion and gene expression were increased by CAI treatment in culture (P< or =0.01), where CAI caused a dose-dependent acidification of the culture milieu (P< or =0.005). This paradox suggests that IL-8 production in vitro may be more sensitive to ambient pH than cytosolic calcium. These observations suggest that CAI inhibition of tumor cell VEGF production and endothelial cell response to VEGF results in disruption of signaling between the tumor and its microenvironment, causing a net anti-angiogenic effect.
Insights
Carboxyamido-triazole (CAI) inhibits tumor growth by reducing vascular endothelial growth factor (VEGF) and blocking endothelial cell responses. This anti-angiogenic agent disrupts tumor signaling, leading to reduced tumor progression.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Tumor growth relies on angiogenesis, the formation of new blood vessels.
- Anti-angiogenic agents are crucial for cancer therapy by inhibiting tumor vascularization.
- Carboxyamido-triazole (CAI) is known to inhibit calcium influx and has shown anti-angiogenic and anti-invasion properties.
Purpose of the Study:
- To investigate the anti-angiogenic mechanisms of Carboxyamido-triazole (CAI).
- To determine if CAI affects pro-angiogenic cytokine production and function.
- To evaluate the impact of CAI on tumor growth and angiogenesis in vivo and in vitro.
Main Methods:
- In vivo studies using human melanoma xenografts treated with oral CAI.
- In vitro experiments assessing CAI's effect on A2058 cell secretion of VEGF and IL-8 under various conditions.
- Analysis of VEGF, HIF-1alpha, and IL-8 gene and protein expression.
- Matrigel plug assay to measure in vivo vascularization.
- Human umbilical vein endothelial cell (HUVEC) migration assays.
Main Results:
- Oral CAI significantly inhibited melanoma xenograft growth and reduced circulating VEGF and IL-8 levels.
- CAI inhibited VEGF secretion by tumor cells under nutrient-limited and acidic conditions.
- CAI reduced VEGF and HIF-1alpha expression and decreased in vivo vascular ingrowth.
- CAI exposure inhibited HUVEC migration towards VEGF.
- A paradoxical increase in IL-8 secretion and gene expression was observed in vitro, linked to CAI-induced media acidification.
Conclusions:
- CAI exhibits anti-angiogenic effects by inhibiting tumor cell VEGF production and disrupting endothelial cell responses to VEGF.
- CAI's mechanism involves downregulating pro-angiogenic factors and interfering with tumor-microenvironment signaling.
- The study highlights CAI's potential as an anti-angiogenic therapeutic agent for melanoma.
Related Concept Videos
Drugs that Stabilize Microtubules
The Tumor Microenvironment
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Mechanism of Angiogenesis
Regulation of Angiogenesis and Blood Supply
Drugs that Destabilize Microtubules

